Imaging features of gastrointestinal toxicity in non-small cell lung cancer patients treated with erlotinib: A single institute 13-year experience.

Pfau, D ; Guler, E ; et al.

In: Clinical imaging, Jg. 68 (2020-12-01), S. 210-217

academicJournal

Objectives: To investigate the imaging features of erlotinib-associated gastrointestinal toxicity (GT) in patients with non-small cell lung cancer (NSCLC).

Materials and Methods: The electronic medical records of 157 patients with NSCLC who received erlotinib between 2005 and 2018 were retrospectively reviewed to identify patients with GT. Clinical and radiologic evidence of erlotinib-associated GT was evaluated. Imaging findings were cross-referenced with clinical presentation, management, and outcomes.

Results: 24 (15%) patients (16 women; median age, 68 years) with radiologic evidence of GT were identified. The median time to detection of GT on imaging was 4.5 months (range: 0-58 months). 3/24 (12.5%) patients had no clinical symptoms, but GT was radiologically identified. Erlotinib-associated GT manifested in the large bowel in either a diffuse (42%) or segmental (58%) pattern. The most common imaging finding was fluid-filled bowel (23/24, 96%).

Conclusion: Erlotinib-associated GT was identified in 15% patients with NSCLC. Fluid-filled colon and segmental involvement were the most common imaging manifestations.

Titel:	Imaging features of gastrointestinal toxicity in non-small cell lung cancer patients treated with erlotinib: A single institute 13-year experience.
Autor/in / Beteiligte Person:	Pfau, D ; Guler, E ; Smith, DA ; Matsunaga, F ; Kikano, EG ; Tirumani, SH ; Dowlati, A ; Ramaiya, NH
Zeitschrift:	Clinical imaging, Jg. 68 (2020-12-01), S. 210-217
Veröffentlichung:	[New York, NY] : Elsevier, [c1989-, 2020
Medientyp:	academicJournal
ISSN:	1873-4499 (electronic)
DOI:	10.1016/j.clinimag.2020.08.017
Schlagwort:	Aged Erlotinib Hydrochloride adverse effects Female Humans Mutation Retrospective Studies Treatment Outcome Carcinoma, Non-Small-Cell Lung diagnostic imaging Carcinoma, Non-Small-Cell Lung drug therapy Lung Neoplasms diagnostic imaging Lung Neoplasms drug therapy
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Clin Imaging] 2020 Dec; Vol. 68, pp. 210-217. <i>Date of Electronic Publication: </i>2020 Aug 26. MeSH Terms: Carcinoma, Non-Small-Cell Lung* / diagnostic imaging ; Carcinoma, Non-Small-Cell Lung* / drug therapy ; Lung Neoplasms* / diagnostic imaging ; Lung Neoplasms* / drug therapy ; Aged ; Erlotinib Hydrochloride / adverse effects ; Female ; Humans ; Mutation ; Retrospective Studies ; Treatment Outcome Contributed Indexing: Keywords: Erlotinib; Gastrointestinal toxicity; Non-small cell lung cancer Substance Nomenclature: DA87705X9K (Erlotinib Hydrochloride) Entry Date(s): Date Created: 20200906 Date Completed: 20201124 Latest Revision: 20201124 Update Code: 20240513

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.